| 000 | 01575 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515094518.0 | ||
| 264 | 0 | _c20080215 | |
| 008 | 200802s 0 0 eng d | ||
| 022 | _a1535-7163 | ||
| 024 | 7 |
_a10.1158/1535-7163.MCT-07-0237 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHuynh, Hung | |
| 245 | 0 | 0 |
_aBevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. _h[electronic resource] |
| 260 |
_bMolecular cancer therapeutics _cNov 2007 |
||
| 300 |
_a2959-66 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aAscites _xpathology |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aBody Weight _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xmetabolism |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xpathology |
| 650 | 0 | 4 |
_aPeritoneal Neoplasms _xpathology |
| 650 | 0 | 4 |
_aSirolimus _xpharmacology |
| 650 | 0 | 4 |
_aTumor Burden _xdrug effects |
| 700 | 1 | _aTeo, Ching Ching Melissa | |
| 700 | 1 | _aSoo, Khee Chee | |
| 773 | 0 |
_tMolecular cancer therapeutics _gvol. 6 _gno. 11 _gp. 2959-66 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1535-7163.MCT-07-0237 _zAvailable from publisher's website |
| 999 |
_c17541447 _d17541447 |
||